Appointment dossier — Melanoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Melanoma
Compounds named in the cited literature for Melanoma, labeled by the strongest evidence found:
- Anti-LAG-3 antibodies — Meta-analysis
- Antibiotics, proton pump inhibitors (PPIs), and probiotics — Meta-analysis
- beta-blockers — Meta-analysis
- biopsy — Meta-analysis
- cancer vaccine therapy — Meta-analysis
- chemotherapy — Meta-analysis
- dabrafenib + trametinib — Meta-analysis
- dabrafenib and trametinib — Meta-analysis
- dabrafenib/trametinib — Meta-analysis
- darovasertib (NVP-LXS196) — Meta-analysis
- effector T-cell therapy — Meta-analysis
- encorafenib/binimetinib — Meta-analysis
- entinostat — Meta-analysis
- high-dose interferon — Meta-analysis
- immune checkpoint inhibitors — Meta-analysis
- Immune checkpoint inhibitors (CTLA-4/PD-1/PD-L1) — Meta-analysis
- ipilimumab — Meta-analysis
- ipilimumab + nivolumab — Meta-analysis
- ipilimumab or nivolumab — Meta-analysis
- ipilimumab plus nivolumab — Meta-analysis
- ipilimumab plus nivolumab — Meta-analysis
- labial reconstruction — Meta-analysis
- liver-directed regional therapies — Meta-analysis
- Mohs micrographic surgery — Meta-analysis
- mRNA-4157/V940 plus pembrolizumab — Meta-analysis
- multimodality treatment — Meta-analysis
- nivolumab — Meta-analysis
- nivolumab — Meta-analysis
- nivolumab — Meta-analysis
- nivolumab + ipilimumab — Meta-analysis
- proton technique with IMRT — Meta-analysis
- proton therapy (SFUD) — Meta-analysis
- pucotenlimab — Meta-analysis
- selumetinib; trametinib — Meta-analysis
- standard surgical excision — Meta-analysis
- surgery — Meta-analysis
- systemic glucocorticoids — Meta-analysis
- tebentafusp — Meta-analysis
- tumor-infiltrating lymphocytes (TIL) — Meta-analysis
- vemurafenib/cobimetinib — Meta-analysis
Open recruiting trials (18)
- NCT05502900 · Phase 3 — Adjuvant Melatonin for Uveal Melanoma (Sweden)
- NCT07230613 · Phase 2 — Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (France)
- NCT06365619 · Phase 2 — Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (United States)
- NCT06630611 · Phase 2 — Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) (Spain)
- NCT05086692 · Phase 1 / Phase 2 — A Beta-only IL-2 ImmunoTherapY Study (United States)
- NCT07285044 · Phase 2 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (United States)
- NCT07215182 · Phase 2 — [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer (Denmark)
- NCT06999980 · Phase 2 — Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (Australia)
- NCT02332668 · Phase 1 / Phase 2 — A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) (United States)
- NCT05620290 · Phase 1 — MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer (Canada)
- NCT05077137 · Phase 1 — A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy (United States)
- NCT04897321 · Phase 1 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (United States)
- NCT07106827 · Phase 1 — A Study of GV20-0251 in Advanced or Refractory Solid Tumors (China)
- NCT04741997 · Early Phase 1 — Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma (United States)
- NCT04986748 — Using QPOP to Predict Treatment for Sarcomas and Melanomas (Singapore)
- NCT07696715 — Timing of Immunotherapy in Melanoma (Netherlands)
- NCT07556380 — Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions (United States)
- NCT06400550 — Identification of Metabolic Phenotypes Associated With Melanoma Metastasis (United States)
Most-relevant first: trials that name Melanoma, then broader trials you may still qualify for. 480 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- I've read that Anti-LAG-3 antibodies has been studied in people for Melanoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Antibiotics, proton pump inhibitors (PPIs), and probiotics has been studied in people for Melanoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that beta-blockers has been studied in people for Melanoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05502900), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?